Table 1b.
Tumour type | Total number of patients /1st line | Standard oncological treatment or standard surveillance or investigation pts/1st line | COVID treatment option with no loss of chance pts/1st line | Delay or pause in treatment or surveillance without major impact pts/1st line | Treatment or abstention with possible impact on tumour growth or symptoms but limited impact on duration of survival pts/1st line | Palliative care approach without impact of COVID pts/1st line |
---|---|---|---|---|---|---|
Urological cancer | 39/25 | 21/15 | 5/3 | 6/4 | 2/2 | 5/1 |
Non prostate GU tumour | 30 | 17/13 | 2/0 | 5/4 | 2/2 | 4/1 |
Prostate cancer | 9 | 4/2 | 3/3 | 1/0 | – | 1/0 |
Brain primary tumours | 17/4 | 3/2 | – | 3/0 | 4/0 | 7/2 |
Glioblastoma/high grade glioma | 14 | 3/2 | – | 1/0 | 4/0 | 6/2 |
Non glioblastoma/high grade gliomas | 3 | – | – | 2/0 | – | 1/0 |
Head and neck carcinoma | 12/7 | 6/2 | 5/4 | 1/1 | – | – |
Lung cancer | 5/3 | 2/1 | – | – | 1/0 | 2/2 |
Breast cancer | 6/3 | 2/1 | 2/1 | 2/1 | – | – |
Gynaecological cancer | 4/2 | – | 1/0 | 2/2 | 1/0 | – |
Gastrointestinal cancer | 2/1 | 2/1 | – | – | – | – |
Cancer of unknown primary site | 3/3 | 2/2 | – | – | – | 1/1 |
TOTAL | 88/48 | 38/24 | 13/8 | 14/8 | 8/2 | 15/6 |
COVID, coronavirus disease.